Deal Library / Pharma BD Deal Intelligence

Rare Disease Deals

The Pharma Closeout tracks 29 deals, $51.6B in disclosed deal value, 12 with a post-close Outcome Score for Rare Disease.

Median Critic Score: 87  ·  Median Outcome Score: 62

Best outcome: Shire plc / Dyax Corp. (89)  ·  Weakest outcome: Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB (20)

All 29 deals

• Shire plc / Dyax Corp. — 2016 · $5.9B · Worked — the deal delivered on its rationale.
• Horizon Pharma plc / Hyperion Therapeutics, Inc. — 2015 · $1.1B · Worked — the deal delivered on its rationale.
• Shire plc / NPS Pharmaceuticals — 2015 · $5.2B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Amolyt Pharma — 2024 · $1.1B · Largely worked — most objectives met.
• Sanofi SA / Inhibrx Inc. — 2024 · $2.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. — 2026 · $1.3B · Largely worked — most objectives met.
• Serapha Bio, Inc. / Boundless Bio, Inc. — 2026 · $230M · Mixed — partial payoff, real shortfalls.
• Shire plc / ViroPharma Incorporated — 2013 · $4.2B · Mixed — partial payoff, real shortfalls.
• Vertex Pharmaceuticals Incorporated / Exonics Therapeutics — 2005 · $1.0B · Mixed — partial payoff, real shortfalls.
• Alexion Pharmaceuticals Inc. / Synageva BioPharma — 2015 · $8.4B · Underwhelmed — fell short of the thesis.
• Astellas Pharma Inc. / Mitobridge, Inc. — 2018 · $450M · Did not work — the deal failed to deliver.
• Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB — 2018 · $855M · Did not work — the deal failed to deliver.
• Neopharmed Gentili S.p.A. (Irish affiliate) / BioCryst Pharmaceuticals, Inc. — 2026 · $345M
• Eli Lilly and Company / Profluent Bio — 2026 · $2.2B
• Chiesi Group / KalVista Pharmaceuticals, Inc. — 2026 · $1.9B
• Neurocrine Biosciences Inc. / Soleno Therapeutics, Inc. — 2026 · $2.9B
• Nippon Shinyaku Co., Ltd. / REGENXBIO Inc. — 2025 · $810M
• BioMarin Pharmaceutical Inc. / Inozyme Pharma, Inc. — 2025 · $270M
• BioMarin Pharmaceutical Inc. / Amicus Therapeutics, Inc. — 2025 · $4.8B
• Servier / Kaerus Bioscience Ltd. — 2025 · $450M
• Norgine / X4 Pharmaceuticals — 2025
• Novo Nordisk A/S / Neomorph Inc. — 2024 · $1.5B
• Sanofi SA / Maze Therapeutics, Inc. — 2023 · $750M
• Ironwood Pharmaceuticals, Inc. / VectivBio Holding AG — 2023 · $1.0B
• AstraZeneca PLC / LogicBio Therapeutics Inc. — 2022 · $70M
• Pfizer Inc. / Vivet Therapeutics S.A.S. — 2020
• Ipsen S.A. / Clementia Pharmaceuticals Inc. — 2019 · $1.3B
• Pfizer Inc. / Vivet Therapeutics S.A.S. — 2019 · $635M
• Pfizer Inc. / Therachon Holding AG — 2019 · $810M

← Deal Library  ·  Interactive search  ·  How we score deals